| Home | E-Submission | Sitemap | Editorial Office
Korean J Hepatol > Volume 15(1); 2009 > Article
The Korean Journal of Hepatology 2009;15(1): 52-58.
doi: https://doi.org/10.3350/kjhep.2009.15.1.52
Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, Lamivudine-resistant chronic hepatitis B patients
Hyun Wook Jung , Moon Seok Choi , Kap Hyun Kim , Sung Hyun Park , Keum Yeon Kwak , Joon Hyoek Lee , Kwang Cheol Koh , Seung Woon Paik , Byung Chul Yoo
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Backgrounds/Aims: It has been shown that adefovir dipivoxil is an effective antiviral agent in the treatment of chronic hepatitis B (CHB), not only in wild-type hepatitis B virus (HBV) infection, but also in lamivudine-resistant (LAMV-R) cases. However, little is known about the durability of the virologic response to adefovir in LAMV-R CHB patients.
Fifteen HBV e-antigen (HBeAg)-positive, LAMV-R CHB patients showed a virologic response to adefovir monotherapy. These patients received additional adefovir for at least a further 12 months. The virologic relapse rate after discontinuation of adefovir was evaluated. In addition, predictive factors associated with virologic relapse were investigated.
The median level of serum HBV DNA before adefovir administration was 7,457,840 IU/mL (range 107,920-99,524,960 IU/mL). The median duration of adefovir treatment was 30 months (range 14-46 months). During a median follow-up period of 14 months after discontinuation of adefovir, the 1-, 2-, 3-, 6-, and 12-month cumulative relapse rates were 26.7%, 53.3%, 73.3%, 80%, and 80%, respectively. High pretreatment HBV DNA levels were found to be the only factor that was predictive of off-therapy relapse.
Our data suggest that the adefovir-monotherapy-induced virologic response is not durable in most patients with LAMV-R HBeAg-positive CHB, especially in those with a high pretreatment HBV DNA level. (Korean J Hepatol 2008;15:52-58)
KeyWords: Adefovir dipivoxil; Lamivudine; Drug Resistance, Viral; Durability
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
Related articles
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B  2016 March;22(1)
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients  2011 December;17(4)
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-na├»ve and nucleos(t)ide analogue-experienced chronic hepatitis B patients  2015 March;21(1)
Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus  2014 June;20(2)
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients  2013 September;19(3)
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association for the Study of the Liver. All rights reserved.